Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review

Pratima Kamada; Arkadiusz Z. Dudek

doi:10.3109/07357900903476794

Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review

Pratima Kamada, Arkadiusz Z. Dudek

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are known to have the potential for cardiotoxicity and should be used with caution in patients with cardiac comorbidities. A retrospective review identified two RCC cases treated with sorafenib in the context of preexisting cardiomyopathy. Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted.

Original language	English (US)
Pages (from-to)	501-504
Number of pages	4
Journal	Cancer Investigation
Volume	28
Issue number	5
DOIs	https://doi.org/10.3109/07357900903476794
State	Published - May 1 2010

Keywords

Cardiac comorbidities
Metastatic renal cell carcinoma
Sorafenib tosylate
Toxicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.3109/07357900903476794

Find It

Find It at U of M Libraries

Cite this

@article{1abf077904714791bfec0d1a2c56ca4b,

title = "Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review",

abstract = "Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are known to have the potential for cardiotoxicity and should be used with caution in patients with cardiac comorbidities. A retrospective review identified two RCC cases treated with sorafenib in the context of preexisting cardiomyopathy. Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted.",

keywords = "Cardiac comorbidities, Metastatic renal cell carcinoma, Sorafenib tosylate, Toxicity",

author = "Pratima Kamada and Dudek, {Arkadiusz Z.}",

year = "2010",

month = may,

day = "1",

doi = "10.3109/07357900903476794",

language = "English (US)",

volume = "28",

pages = "501--504",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction

T2 - Report of two cases and literature review

AU - Kamada, Pratima

AU - Dudek, Arkadiusz Z.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are known to have the potential for cardiotoxicity and should be used with caution in patients with cardiac comorbidities. A retrospective review identified two RCC cases treated with sorafenib in the context of preexisting cardiomyopathy. Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted.

AB - Targeted therapies used in the treatment of metastatic renal cell carcinoma (RCC) are known to have the potential for cardiotoxicity and should be used with caution in patients with cardiac comorbidities. A retrospective review identified two RCC cases treated with sorafenib in the context of preexisting cardiomyopathy. Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted.

KW - Cardiac comorbidities

KW - Metastatic renal cell carcinoma

KW - Sorafenib tosylate

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=77952207351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952207351&partnerID=8YFLogxK

U2 - 10.3109/07357900903476794

DO - 10.3109/07357900903476794

M3 - Article

C2 - 20014944

AN - SCOPUS:77952207351

SN - 0735-7907

VL - 28

SP - 501

EP - 504

JO - Cancer Investigation

JF - Cancer Investigation

IS - 5

ER -

Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review

Abstract

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this